After his sinister role on The Handmaid’s Tale, Josh Charles is switching gears to Fox’s upcoming small town show Best ...

The stock's rise snapped a four-day losing streak.

On Monday, Chase Infiniti proved her breakout star status with a Golden Globe nomination for her role in One Battle After ...

Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Arcus Biosciences (RCUS) stock falls as the company and partner Gilead (GILD) halt a Phase 3 cancer trial evaluating its anti ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

This was the stock's second consecutive day of gains.

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.